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INTRODUCTION
There are nearly 40 million people worldwide living
with HIV infections, and numbers of newly infected
patients reported last year were at a record high
(UNAIDS, 2006). The WHO initiative ‘3by5’, launched
in 2003 (WHO, 2003a), aimed to treat 3 million peo-
ple with antiretroviral therapy (ART) by the end of
2005, but has unfortunately not met its targets with
only around 1.33 million people receiving ART world-
wide, while an estimated 6.5 million people need ART
(WHO/UNAIDS, 2006). The situation remains particu-
larly bad in poorer regions, such as sub-Saharan
Africa, where ART coverage is as low as 17% (WHO/
UNAIDS, 2006). The difﬁculty in providing adequate
medical treatment is still a major problem in countries
with limited resources. Very often, this is not only a
matter of making ﬁnancial resources and antiretroviral
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SUMMARY
The decision to provide antiretroviral therapy to HIV-positive patients
mainly depends on the CD4
+ T-cell count, with therapy indicated at a
cut-off value of <350–200 CD4
+ Tc e l l s / ll blood. Monitoring patients is
still a major problem in countries with limited resources where blood
samples often have to be transported over long distances to regional
referral centres in which the count can be performed on ﬂow
c y t o m e t e r s .W eh a v ee v a l u a t e dan e w l yd e v e l o p e ds i m p l ea n d
inexpensive method for CD4
+ T-cell quantification. It is a variation of
the Invitrogen T4 Quant kit, with manual isolation of nuclei from CD4
+
T cells and subsequent counting on the small haematology analyser
pocH-100i, Sysmex. We have demonstrated that this new method is
highly reproducible and gives stable and linear results over a wide
range of CD4
+ T-cell concentrations. Method comparison to two
different flow cytometers showed excellent correlation with concor-
dances of about 93%. Overall, this method is rapid, easy to perform
and offers a good reliable alternative to measurement by flow
cytometry. The pocH-100i has the additional benefit of providing a
complete blood count with a three-part white blood cell differential
and software for patient data storage and handling.
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providing access to the required medical services, not
only in regional referral centres or district hospitals
but also in local primary health-care centres (WHO,
2003b). While this approach has been partly success-
ful for making antiretroviral medication available in
certain countries of sub-Saharan Africa, laboratory
tests used for the staging and monitoring of HIV
patients are still not commonly available in local
health-care centres (Baggaley, Garnett & Ferguson,
2006; The Global Fund, 2007; WHO/UNAIDS, 2007).
The current method used for staging HIV infection in
settings with limited resources is the sole measure-
ment of CD4
+ T cells (‘CD4 test’). WHO recommends
a cut-off value of 200–350 CD4
+ T cells/ll for adults;
patients with values below this should receive ART
(WHO, 2003b). In children, the absolute CD4
+ T-cell
numbers can vary considerably and is therefore not a
suitable staging marker. It is recommended by WHO
and the Centers for Disease Control that the percent-
age of CD4
+ T cells should be used for children under
5 years of age. The suggested cut-off values are 25%
for infants up to 11 months of age, <20% for children
up to 3 years and <15% for children between 3 and
5 years of age (Centers for Disease Control, 1994; HIV
Paediatric Prognostic Markers Collaborative Study,
2005; WHO, 2006).
The CD4 count is usually routinely performed
using ﬂow cytometry, but these instruments are gen-
erally only available in regional referral centres
because of their expense and the skill needed to oper-
ate them. Frequently, blood samples have to be trans-
ported over long distances, so samples received are
not in an ideal condition for CD4
+ T-cell measure-
ments because of their age and there is often consid-
erable delay of up to 3 weeks in the results being
available to the referring centre. There is an urgent
need for a CD4 test that can be performed in a pri-
mary health-care centre, using inexpensive, simple-
to-use, point-of-care equipment. In addition, as the
management and transmission of patient and labora-
tory data are still a problem in resource-limited set-
tings, it would be desirable to have complementary
software that allows simple data management and
transmission of the laboratory report via e-mail.
The T4 Quant kit from Invitrogen (Carlsbad, CA,
USA, formerly Dynal Biotech) has been a manual
alternative for CD4 testing for some years (Diagbouga
et al., 2003; Bi et al., 2005). The CD4
+ T-cell concentra-
tion can be quantitated by a simple and inexpensive
procedure, using magnetic beads coated with appropri-
ate antibodies to separate CD4
+ T cells from whole
blood samples. A major advantage of this procedure is
that it requires no complex technical equipment but
on the downside it does not quantitate other cell pop-
ulations or offer any ﬂexibility in the data output. As
it cannot supply a complementary leucocyte count
there is no possibility of evaluating the number of
CD4
+ T cells as a percentage, which is highly recom-
mended for children by the WHO.
A potential solution to this is to perform a CD4
count on a simple inexpensive point-of-care haema-
tology analyser. With this, the laboratory has the
opportunity to run both the three-part differential
blood count and the CD4 count on one instrument
without the need to purchase additional ﬂow cyto-
metric equipment, which should contribute to
reduced costs. As it is not possible to count the CD4
+
T cells directly on the analyser while they are still
attached to the magnetic beads, the method has been
modiﬁed. Firstly, it is crucial to remove the CD4
+
monocytes from the sample, so that they do not inter-
fere with the CD4
+ lymphocyte count. This is carried
out by binding them to CD14 covered magnetic beads
and removing them on the magnetic rack. After that,
all remaining CD4
+ cells in the sample (lymphocytes
only) will get isolated by the use of CD4
+ magnetic
beads. They are then incubated with a speciﬁc lysis
solution (supplied) so that the CD4
+ T cells lyse and
release their nuclei. The beads are collected with a
magnet and discarded. The remaining ﬂuid containing
the nuclei of the CD4
+ T cells can then be counted on
the Sysmex pocH-100i haematological analyser. The
pocH-100i is a compact automated haematology ana-
lyser designed speciﬁcally for point-of-care testing
(Briggs et al., 2003). As well as counting the CD4
+
nuclei, the analyser provides a full blood count and a
three-part differential leucocyte count, the results of
which are valuable for monitoring the possible side
effects of ART.
We have developed and evaluated the performance
of the T4 Quant kit in a modiﬁed format optimised for
automated cell counting on the pocH-100i, using dedi-
cated software. Linearity, stability and lot-to-lot reagent
variation have been evaluated for the new system and
the CD4
+ T-cell counts were compared with a ﬂow
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+ T CELLS WITH THE SYSMEX POCH-100Icytometric method as the designated comparison
method. This study demonstrates a simple and robust
procedure for the isolation and counting of CD4
+ T cells.
MATERIALS AND METHODS
One hundred and ﬁfteen residual EDTA blood samples
from HIV-positive patients and 21 samples from
patients with leukaemia or lymphoma were obtained
from Haematology Department, University College
London Hospital, UK. Measurements were performed
on the day of the phlebotomy or the next day.
Isolation and counting of the CD4
+ T cells
Isolation and counting of the CD4
+ T cells require the
Dynal T4 Quant Kit/Reagent Kit for Sysmex Analysers
(Invitrogen, Oslo, Norway), and the components of
the Sysmex CD4 system, namely: a pocH-100i with
K-XPERT CD4 data management software for appropriate
calculation of CD4
+ T cells (Sysmex Europe, Norder-
stedt, Germany), a tube rotator, a microcentrifuge, a
magnet rack, two pipettes (50 and 250 ll) and capped
plastic tubes (1.5 ml). The isolation procedure was
carried out according to the manufacturer’s protocol
and as demonstrated in Figure 1. In brief, 250 ll
EDTA blood was diluted with 250 ll washing buffer
and incubated with 50 ll of magnetic beads coated
with an anti-CD14 antibody (CD14 Dynabeads
 ) for
10 min. The beads with the monocytes attached were
then removed by incubation on the magnet rack for
3 min (step A). A total of 500 ll of the monocyte-free
supernatant was incubated with 50 ll CD4 Dynabe-
ads
  on the tube rotator for 10 min at 50 rpm (step
B), then the beads with the CD4
+ T cells attached
were separated and washed on the magnet rack
(2 · 3 min, step C). The tube was removed from the
rack and 100 ll lysis solution was added to release the
nuclei of the CD4
+ T cells (10 min). After lysis,
the tube was again placed in the magnet rack to
remove the beads (3 min, step D). The supernatant
was transferred into a fresh tube and the nuclei of the
CD4
+ T cells were counted on the pocH-100i in the
white blood cell (WBC) channel (step E).
By performing a complete blood count (CBC) on
the same instrument, it is possible to measure both,
the absolute CD4
+ T-cell concentration and indirectly
the corresponding value as a percentage of the total
Step E
Count lymphocyte nuclei
with pocH-100i
Monocytes
Other cells
CD4
+ T lymphocyte nuclei
Dynabeads
CD4
+ T lymphocytes
Step  A
Remove monocytes  
Step B 
Retain CD4+ T lymphocytes 
and remove other cells
Step C
Wash CD4+ T 
lymphocytes  
Step D
Lyse CD4+ T lymphocytes
and release nuclei  
10 min + 3 min 10  min + 3  min
3 min + 3 min
10 min + 3 min
Figure 1. Flow chart of the
immunomagnetic isolation
procedure. After the removal of
monocytes with anti-CD14 cov-
ered magnetic beads (step A),
anti-CD4
+ covered immunomag-
netic beads are used to isolate
CD4
+ T cells from whole blood
samples (step B). The CD4
+ T
cells are washed and lysed in
the same tube and ﬁnally the
free nuclei are counted on the
pocH-100i haematology analyser
to estimate the number of CD4
+
T cells/ll blood.
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and data from one sample are shown in Figure 2. By
using the full capacity of the magnetic racks, up to 12
patient samples can be analysed per hour by a single
experienced operator.
Imprecision
Blood samples with varying concentrations of CD4
+ T
cells were used to assess imprecision. To asses the
within-run imprecision of the ﬁnal measurement step
alone, ﬁve blood samples with WBC concentrations
between 1600 and 100 cells/ll were measured 10
times consecutively on the pocH-100i haematology
analyser. The total imprecision of the method was
then measured by selecting ﬁve different blood sam-
ples with varying CD4
+ T-cell concentrations
(between 70 and 855 cells/ll), estimated by ﬂow
cytometry. Each of these samples were split into 10
aliquots and the CD4
+ T-cell nuclei were isolated
according to the immunomagnetic separation protocol
and counted in triplicate on the pocH-100i.
Linearity
Linearity was measured according to the ICSH (1994)
guidelines. A blood sample containing 1660 CD4
+
T cells/ll was serially diluted up to 16-fold. The CD4
+
T-cell nuclei were measured in triplicate for each
dilution.
Sample stability
Three blood samples were selected with varying con-
centrations of CD4
+ T cells. Each sample was aliquoted
into three tubes which were then stored at 4, 20 and
37  C, respectively. The isolation and measurement
was performed immediately and after 24 and 48 h.
Methods comparison
The methods comparison comprised 115 samples from
HIV-positive patients. CD4
+ T-cell concentrations as
quantitated by ﬂow cytometry ranged from 7 to 1392/
ll. All samples were analysed by immunomagnetic
isolation of CD4
+ T cells with subsequent measure-
ment on the pocH-100i and compared with two differ-
ent ﬂow cytometric methods: Beckman Coulter Epics
 
CD4
CD4%
CD4# 0.402 10e3/µl
33.23 %
WBC
LYMPH%
LYMPH#
MXD%
MXD#
NEUT%
NEUT#
5.4 10e3/µl
3.6 10e3/µl
0.5 10e3/µl
1.3 10e3/µl
24.7 %
8.7 %
66.6 %
LYMPH 
NEUT
MXD
GHOST 
(a)
(b)
Figure 2. Screenshots depicting the histograms and
numerical results for WBC (a) and CD4
+ T-cell (b)
count from one blood sample. MXD = the sum of
monocytes, eosinophils and basophils.
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TM Flow Cytometer, SYSTEM II SOFTWARE, version
3 using the Cyto-stat tetraCHROME CD45-FITC/CD4-
RDI/CD8-ECD/CD3-PC5 reagent kit and the TETRAONE
SYSTEM software version 1 (all Beckman Coulter,
Miami, FL, USA) and BD FACSCalibur using CELLQUEST
software and BD CD45/CD3/CD4/CD8 monoclonal
antibodies (Beckton Dickinson, Franklin Lakes, NJ,
USA). The data were compared by statistical correla-
tion analysis using Spearman’s (1904) rank correlation
coefﬁcient. Regression equations were calculated
according to Passing & Bablok (1983); agreement was
assessed with Bland–Altman plots.
Lot-to-lot reagent variation
Fifty-four patient samples were measured simulta-
neously using two different lots of the Dynal T4
Quant kit/Reagent kit for Sysmex analysers.
Effect of abnormal lymphocytes on the assay
To assess whether abnormal lymphocytes affect the
manual isolation step 21 samples from patients with
leukaemia or lymphoma were tested in duplicate for
the immunomagnetic separation of CD4
+ T cells fol-
lowed by measurement on the pocH-100i and com-
pared with counts from the Epics XL ﬂow cytometric
method.
RESULTS
Imprecision
The results show acceptable within-run imprecision
with a coefﬁcient of variation (CV) between 3.9% and
8.1% for concentrations of 100–1600 CD4
+ T cells/ll.
The total imprecision of the method, isolation of the
nuclei and counting on the pocH-100i demonstrated
increasing imprecision with lower CD4
+ T-cell num-
bers; the CV was, however, still only about 16% at the
cut-off level of 200 CD4
+ T cells/ll and about 12% at
350 CD4
+ T cells/ll, as demonstrated in Table 1.
Linearity
The manual isolation and counting of CD4
+ T-cell
nuclei demonstrated excellent linearity in the evalu-
ated range between 100 and 1600 cells/ll (Figure 3).
Stability
Results for stability are demonstrated in Figure 4.
Samples were stable for 24 h when stored at 4 or
20  C with an unsteady decline of CD4
+ T-cell counts
of 15% maximum, which is within the range of the
expected imprecision of the method. Longer storage at
these temperatures led to further decrease of CD4
+
T-cell counts.
Table 1. Concentration dependence of the CV
of immunomagnetic isolation with subsequent
measurement of CD4
+ T-cell nuclei on the Sysmex
pocH-100i
CD4
+ T cells/ll whole blood CV (%)
27.7 18.0
135.8 13.8
198.1 16.3
384.6 11.3
654.4 11.6
CV, coefﬁcient of variation. The determined imprecision
includes the imprecision of the manual isolation step
plus that of the measurement.
y = 1.0161x – 9.5367
R 2 = 1.00
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Figure 3. Linearity of the immunomagnetic isolation
and subsequent measurement of the CD4
+ T-cell
nuclei on the pocH-100i (coefﬁcients were calculated
by linear regression).
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+ T
cells decreased over the course of time; the higher the
temperature, the greater the loss of CD4
+ T-cell
nuclei.
Methods comparison and concordance analysis
Comparison of results between the immunogenic iso-
lation with automated counting and the two ﬂow cy-
tometric methods demonstrates good correlation.
Figure 5a,b shows the correlation analysis and Bland–
Altman agreement for the comparison of the manual
method and the Epics XL ﬂow cytometer. Comparison
with the FACScalibur ﬂow cytometer produced similar
results for agreement and correlation, with the Spear-
man’s rank correlation coefﬁcient R being 0.93 for
CD4
+ T cells/ll and 0.86 for CD4 percentage.
However, both ﬂow cytometric methods demon-
strated higher CD4
+ T-cell counts than the immuno-
magnetic separation with pocH-100i count. On
average, results from the Epics XL were 16.6%
higher than the pocH-100i and 23.6% higher on the
FACSCalibur. Concordance between the different
methods was determined by means of contingency
tables, classifying results as to whether they were
higher or lower than the minimum cut-off value of
200 CD4
+ T cells/ll (Table 2a,b). Both methods
picked up similar numbers of the same patients with
critical CD4 values of 200/ll and below (n = 57 and
55, respectively), or with CD4
+ T-cell concentrations
above 200/ll (58 and 60, respectively). Using this
cut-off value, the concordance with the Epics XL was
93.1%. With the data management software K-XPERT
(Droest, 2002), the pocH-100i offers the possibility
for the user to introduce a calibration factor. After
introducing a calibration factor of 1.166 to compen-
sate for the generally higher values on the Epics XL,
the concordance was reassessed and found to be
exactly the same at 93.1%. The concordances with
the results obtained with the FASCalibur were
93.4%, both with and without calibration factor
(data not shown).
As it is more advisable to estimate the percentage
of CD4
+ T cells (CD4 percentage) in patients <5 years
of age, rather than the absolute count, we tested
whether the pocH-100i method could allow for this
paradigm. We assessed the CD4 percentage from the
immunomagnetic isolation with automated counting
and the internal total lymphocyte count from the
pocH-100i and compared it with the CD4 percentage
data from the Epics XL and the FACSCalibur. Fig-
ure 5c,d demonstrates the correlation and agreement
for the manual method and the Epics XL.
Lot-to-lot reagent variation
Two different lots of Dynal magnetic beads and
reagents were used to determine CD4
+ T-cell concen-
trations. Both of them demonstrated comparable
results on all samples (Figure 6).
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Figure 4. Demonstration of sam-
ple stability of samples after
storage for up to 48 h at 4, 20
and 37  C, respectively.
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We also quantiﬁed CD4
+ cells on 21 blood samples
from patients with leukaemia or lymphoma by immu-
nomagnetic isolation and counting on the pocH-100i
and compared the results with those generated on the
Epics XL ﬂow cytometer (Table 3). Although, with an
average CV value of 4%, the reproducibility of the
immunomagnetic separation was as good as with sam-
ples from HIV patients (data not shown), results were
often quite diverse. This was particularly true for
patients with a high lymphocyte concentration and
highly abnormal cells present.
DISCUSSION
The measurement of CD4
+ T cells is the most impor-
tant test for the staging and therapeutic monitoring of
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Figure 5. Methods comparison of immunomagnetic isolation with subsequent measurement of the CD4
+ T-cell
nuclei/ll (a, b) or CD4 percentages (c, d) on the pocH-100i with ﬂow cytometric measurements on the Epics
depicted are Passing and Bablok regressions with the 95% conﬁdence interval (dashed lines), Spearman’s rank
correlation coefﬁcient R and Bland–Altman plots.
Table 2. Concordance between immunomagnetic iso-
lation with consecutive measurement of the CD4
+
T-cell nuclei on the pocH-100i and ﬂow cytometric
measurement on the Epics XL (a) and after application
of the respective calibration factor (b)
n = 115
Epics XL
200/ll
Epics XL
>200/ll
(a) pocH-100i vs. Epics XL (not calibrated) (%)
pocH-100i > 200/ll 5 (4.3) 55 (47.8)
pocH-100i  200/ll 52 (45.2) 3 (2.6)
(b) pocH-100i vs. Epics XL (calibrated) (%)
pocH-100i > 200/ll 7 (6.1) 57 (49.6)
pocH-100i  200/ll 50 (43.5) 1 (0.9)
Concordance 93.1%. Discordance 6.9%.
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+ T CELLS WITH THE SYSMEX POCH-100I 175HIV-infected patients in resource-limited settings. The
lack of simple and affordable CD4 tests has been a
major obstacle for bringing antiretroviral treatment to
patients in more remote locations in Africa and other
areas. Currently, samples are usually sent to distant
regional referral centres. The quality of the blood sam-
ples is affected by the transport and time delay. In
centralized testing centres, the samples are usually
analysed by ﬂow cytometry which is costly and
requires skilled operators. Centralized testing results
in a delay in the results being available with a conse-
quent delay in treating the patient. In South Africa
and Botswana, some of the authors observed turn-
around times of 3 weeks and longer even when the
testing centres are located <50 km from the primary
health-care centre. Delayed reporting has a negative
impact on disease management and without a means
of recalling the patient for treatment when the results
do arrive treatment is often not initiated. It would
Lot to lot variation (CD4+ T cells/µl)
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Figure 6. Lot-to-lot reagent variation of immunomag-
netic isolation with measurement of the CD4
+ T-cell
nuclei on the pocH-100i.
Table 3. Comparison of immunomagnetic isolation with measurement of the CD4
+ T-cell nuclei on the pocH-100i and
ﬂow cytometric measurement on the Epics XL in patients with leukaemia and lymphoma
No.
pocH-100i
CD4/ll blood
Epics XL
CD4/ll blood
Lymphocytes/ll
blood Diagnosis
1 6394 47 623 50 200 T-cell lymphoma, many very atypical lymphocytes
2 950 5556 11 400 Plasma cell leukaemia, many circulating plasma cells
3 408 136 4040 Hodgkin’s disease/CLL
4 821 1855 13 190 CLL
5 785 630 7140 Hodgkin’s disease
6 1347 1385 5160 NHL
7 623 554 54 990 CLL
8 903 882 35 900 B-cell lymphoproliferative disease, not characterized
9 580 854 2610 Pre-B ALL
10 1024 1960 21 750 NHL
11 987 1279 6470 B-cell Lymphoma
12 934 1419 15 370 NHL
13 489 423 1130 Mantle cell lymphoma, many apoptotic lymphocytes,
occasionally blasts
14 571 1071 2750 ALL 4% blasts
15 375 2223 8380 ALL 84% blasts
16 1114 Not gateable 22 650 AML 58% blasts, 22.65 · 10
9/l lymphocytes
17 112 74 17 610 Lymphoma, many smear cells present
18 1345 1324 59 290 B-CLL 5–10% prolymphocytes
19 1054 1198 5270 AML 87% blasts
20 1737 2331 20 097 Precursor B-ALL,CD10-positive 15% blasts
21 1129 2369 8450 Precursor B-ALL, CD10-negative, 90% blasts
CLL, chronic lymphatic leukaemia; NHL, non-Hodgkin lymphoma; ALL, acute lymphatic leukaemia; AML, acute mye-
loid leukaemia; Not gateable, Epics XL automated software was unable to gate on the CD4
+ population of lymphocytes.
Total lymphocyte numbers were counted on the Sysmex XE-2100.
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+ T CELLS WITH THE SYSMEX POCH-100Itherefore be desirable to perform the CD4 tests at the
local hospital or even at the primary health-care cen-
tres where the patient delivers a blood sample and
can wait for the CD4 result and receive appropriate
medical counselling and treatment if required all in
one visit. As well as keeping the patient’s data on ﬁle
in the primary health-care centre, it should be possi-
ble to make these data available to the remote referral
centres for the purpose of surveillance, epidemiology
and health-care policy.
The proposed CD4 point of care testing (POCT) sys-
tem can be performed by a nurse, health worker or
medical technician after the person has received appro-
priate training. In addition to hands-on training, the
manufacturer supplies a training DVD, showing all
the steps of the assay in a detailed and simple way. As
the samples are processed in parallel, a trained person
can perform up to 12 tests per hour. It is possible to use
software developed for the system to keep track of
previous haematological data of the individual patient,
which is beneﬁcial for treatment decisions by the
health-care staff. For between-run imprecision, the CV
has been determined to be around 16% at the WHO
recommended minimum cut-off level of 200 CD4
+ T
cells/ll. The test results are linear between 100 and
1660 CD4
+ T cells/ll.
The methods comparison with two ﬂow cytometric
methods demonstrated a generally good correlation
over the whole concentration range. The results were
slightly higher by ﬂow cytometry as compared with
immunomagnetic isolation with subsequent measure-
ment of CD4
+ T cell nuclei on the pocH-100i. A possi-
ble explanation is a small loss of cells during the
separation procedure. Some CD4
+ T cells might
be unstable and disintegrate during the isolation
procedure.
Data from the last ﬁve surveys of participants of
the UK National External Quality Assurance Schemes
(NEQAS) for leucocyte immunophenotyping demon-
strated an inter-laboratory variability of ﬂow cyto-
metric CD4 tests ranging from CVs of 9% to 14%
on counts from 133 to 827 CD4
+ T cells/ll.
Therefore, the deviation between the immunoma-
gnetic isolation with subsequent measurement of
CD4
+ T-cell nuclei on the pocH-100i and the ﬂow
cytometric measurement is acceptable, especially
because to date an internationally recognized
reference procedure for the measurement of CD4
+ T
cells does not exist; however, a routine dual-platform
ﬂow cytometry system was selected as the designated
comparison method for this study.
From a clinical point of view, concordance between
the methods is important because patients are classi-
ﬁed and scheduled for treatment or not according to
whether the measurement result is above or below a
protocol-deﬁned cut-off value. The concordance
between immunomagnetic isolation and consecutive
measurement of CD4
+ T-cell nuclei on the pocH-100i
and ﬂow cytometric measurement on the Epics XL
and FACSCalibur was 93.1% and 93.4%, respectively.
The concordance rate remained the same after the
immunomagnetic isolation and measurement of CD4
+
T-cell nuclei on the pocH-100i has been calibrated to
ﬂow cytometry. Probably because of different method-
ology, we found a constantly lower absolute CD4
count compared with the ﬂow cytometers. To account
for this difference, we developed a calibration factor
in the K-XPERT software settings. This calibration caused
reclassiﬁcation of four of 115 patients (3.5%) from
below the cut-off value to above the cut-off value on
the pocH-100i. As two of these patients were below
the cut-off value on the Epics XL and two were above
the overall concordance did not change. The same sit-
uation occurred for the FACSCalibur. If locally
required, the immunomagnetic isolation and measure-
ment of CD4
+ T-cell nuclei on the pocH-100i may be
calibrated to ﬂow cytometry.
Because of the high variability of the total lympho-
cyte concentration in children, the WHO recommends
that the absolute CD4
+ T-cell concentration is not
used for children under 5 years of age. Instead, the
percentage of CD4
+ T cells should be used (HIV Paedi-
atric Prognostic Markers Collaborative Study, 2005;
WHO, 2006). As the pocH-100i can measure the total
lymphocyte concentration, it is suitable for CD4 test-
ing in accordance with WHO recommendations for
both adults and children. In addition, the method
comparison studies of this work clearly show that esti-
mations of CD4 percentages correlate well with the
results from the ﬂow cytometers.
In patients with leukaemia or lymphoma, the two
methods sometimes gave quite different results. It is
not possible to say which method is more accurate as
the standardized gating procedure on the ﬂow cyto-
meter might not apply for some of these samples. In
one case, automated gating was even impossible. While
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leukaemias, the occurrence of non-Hodgkin lympho-
mas (NHL) has been increasing, with HIV-positive
patients being around 350 times more likely to develop
an NHL (Goedert, 2000) than non-infected people.
However, the pocH-100i will provide a ‘ﬂag’ in the
presence of abnormal WBC, blasts or atypical lympho-
cytes, which should alert operators to look at the blood
ﬁlm morphology of the cells and treat the CD4
+ T-cell
results with caution if lymphoma cells are present or
refer the sample to a specialized regional centre.
The sample stability experiments demonstrated that
the samples were stable at 4 and 20  C for 24 h.
Longer storage as well as higher temperatures led to
an impaired recovery of CD4
+ T cells. Sample stability
is generally a problem for CD4 analysis, including
ﬂow cytometric measurements (Diagbouga et al.,
2003). For immunomagnetic isolation and measure-
ment of CD4
+ T-cell nuclei on the pocH-100i, the
blood samples should therefore be stored in a refriger-
ator and measured preferably within 24 h. This should
be achievable in a primary health-care centre as the
whole measurement procedure is performed on site as
POCT; the pre-analytical conditions can be much bet-
ter controlled than in centralized testing where long
distance transport can be a crucial factor. The compar-
ison of two different reagent lots demonstrated no rel-
evant lot-to-lot variation.
The concept of using a point-of-care haematologi-
cal analyser to measure CD4
+ T cells in primary
health-care centres includes the additional beneﬁts of
having the possibility to perform a CBC and a three-
part differential blood count on any patient requiring
it (Figure 2). This is important because monitoring of
ART requires haematological measurements as most
drugs used for treatment can cause anaemia and
neutropenia.
By following the ambitious WHO ‘3by5’ (WHO,
2003a; WHO/UNAIDS, 2006) initiative, the number of
HIV/AIDS patients getting antiretroviral treatment is
expected to increase extensively. The central
organization of the data accumulating at rural health-
care facilities in the future will be a great challenge
which can only be handled by electronic data process-
ing. Data from the pocH-100i can easily be transferred
to regional referral hospitals or a central data bank,
using the complementary data management software
K-XPERT, allowing for a higher standard of quality
assurance. Furthermore, the K-XPERT provides simple
graphical and numerical tools which help to identify
and combine all data for each patient which is an
important point for the monitoring of ART. This
method for measuring CD4
+ lymphocytes offers an
alternative to the expensive ﬂow cytometry count
with the advantage that it is rapid and simple to per-
form in all laboratories without the need for complex
skills and equipment.
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